# Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults

> **NCT06523595** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 31 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** VX-993
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT06523595
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-31
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06523595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06523595, "Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06523595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*